This federal contract award, valued at $13,760,224.00, was issued by the National Cancer Institute (NCI) to Fisher Bioservices Inc., a subsidiary of Thermo Electron Corporation. The contract is for the registration, storage, and distribution of chemicals and drugs to support pre-clinical discovery, evaluation, and development. This is a delivery order contract with a cost-plus-fixed-fee pricing type, and it has an ultimate completion date of February 29, 2028.
The contract is not set aside for any specific business type. Fisher Bioservices has extensive experience as both a prime contractor and subcontractor on federal contracts and grants supporting biomedical research and public health initiatives, including previous awards from the NCI, the National Institute of Allergy and Infectious Diseases, and the Department of the Army. The company also holds two significant indefinite delivery contracts (IDVs) with federal agencies, one with the NCI and another with the National Institute of Allergy and Infectious Diseases, which further demonstrate its capability to provide comprehensive support for critical stages of drug discovery and development within major federal research programs.
Generated 2/26/25, 9:49 AM